RCT | Enzalutamide versus standard antiandrogen therapy in hormone-sensitive prostate cancer with metastasis

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: ENZAMET shows promise as prostate cancer treatment – University of Adelaide